Literature DB >> 3418540

Opioid modulation of the response of preoptic neurones to stimulation of the ventral noradrenergic tract in female rats.

R G Dyer1, R Grossman.   

Abstract

1. Experiments were undertaken on twenty-nine ovariectomized female rats, pretreated with oestrogen and anaesthetized with urethane, to test the hypothesis that opioid peptides regulate noradrenergic transmission in the medial preoptic area and thereby influence the neural circuitry controlling the secretion of luteinizing hormone. 2. Extracellular recordings were obtained with glass micropipettes from ninety-four neurones in the medial preoptic area. These recordings were continued whilst both the ventral noradrenergic tract, the noradrenergic projection to the medial preoptic area, and orthodromic pathways originating in the arcuate nucleus, the main source for endogenous opioid peptides in the hypothalamus, were stimulated electrically. Forty of the ninety-four neurones responded to stimulation at one or both of the test sites. 3. Electrical stimulation of the ventral noradrenergic tract excited fifteen neurones (greater than 30% change in number of action potentials recorded during the 'response time period') and inhibited a further ten cells. When the nucleus arcuatus was stimulated electrically thirteen cells were inhibited and twelve neurones showed an excitatory response. 4. The opioid antagonist naloxone (80 mM) and/or morphine (50 mM) were ejected into the immediate vicinity of eighty-six of the recorded cells by passage of balanced currents (range 15-80 nA) through a multi-barrelled electrode glued to the recording electrode. The tip of the drug-containing electrode was about 15-25 microns behind the tip of the recording electrode. 5. The ionophoretic application of naloxone, during electrical stimulation of the ventral noradrenergic tract, diminished the inhibitory response in four of ten cells and enhanced the excitatory response in nine out of fifteen neurones. By contrast, morphine diminished the excitatory response in seven of these fifteen cells tested, an effect that was prevented by the simultaneous application of naloxone. 6. Similarly, the application of naloxone during stimulation of the nucleus arcuatus reduced the inhibitory effect in eight out of thirteen cells. When four of these eight responsive neurones were exposed to morphine either the effect of naloxone was reversed or, when given alone, the inhibition was enhanced. 7. Finally, for seventeen cells categorized as non-responsive to stimulation at either site, the application of naloxone during hind brain stimulation revealed an excitatory input from the ventral noradrenergic tract in seven cases. 8 The experiments demonstrate that opioid peptides modulate the neural inputs to the medial preoptic area arising from the nucleus arcuatus and the ventral noradrenergic tract.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418540      PMCID: PMC1191827          DOI: 10.1113/jphysiol.1988.sp017140

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  26 in total

1.  Inhibition of the release of pituitary ovulatory hormone in the rat by morphine.

Authors:  C A BARRACLOUGH; C H SAWYER
Journal:  Endocrinology       Date:  1955-09       Impact factor: 4.736

2.  Effect of neonatal testosterone upon opioid receptors and the content of beta-endorphin, neuropeptide Y and neurotensin in the medial preoptic and the mediobasal hypothalamic areas of the rat brain.

Authors:  F J Diez-Guerra; R J Bicknell; S Mansfield; P C Emson; R G Dyer
Journal:  Brain Res       Date:  1987-10-27       Impact factor: 3.252

3.  Gonadotropin secretion following intraventricular norepinephrine infusion into neonatally androgenized female rats.

Authors:  R J Handa; T P Condon; D I Whitmoyer; R A Gorski
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

4.  Morphine decreases luteinizing hormone by an action on the hypothalamic-pituitary axis.

Authors:  T J Cicero; T M Badger; C E Wilcox; R D Bell; E R Meyer
Journal:  J Pharmacol Exp Ther       Date:  1977-12       Impact factor: 4.030

5.  Evidence for noradrenergic mediation of opioid effects on luteinizing hormone secretion.

Authors:  S P Kalra; J W Simpkins
Journal:  Endocrinology       Date:  1981-09       Impact factor: 4.736

6.  Electrical stimulation of the ventral noradrenergic tract (VNAT) releases hypothalamic noradrenaline and stimulates prolactin secretion in ovariectomized female rats treated with oestrogen.

Authors:  A D Dean; S Mansfield; R G Dyer
Journal:  Neurosci Lett       Date:  1985-06-04       Impact factor: 3.046

7.  Effects of naloxone on catecholamine and LHRH release from the perifused hypothalamus of the steroid-primed rat.

Authors:  C A Leadem; W R Crowley; J W Simpkins; S P Kalra
Journal:  Neuroendocrinology       Date:  1985-06       Impact factor: 4.914

8.  Opioid peptides inhibit the release of noradrenaline from slices of rat medial preoptic area.

Authors:  F J Diez-Guerra; S Augood; P C Emson; R G Dyer
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

9.  Modulation of endogenous opioid influence on luteinizing hormone secretion by progesterone and estrogen.

Authors:  S M Gabriel; J W Simpkins; S P Kalra
Journal:  Endocrinology       Date:  1983-11       Impact factor: 4.736

Review 10.  Endogenous opioid peptides and hypothalamic neuroendocrine neurones.

Authors:  R J Bicknell
Journal:  J Endocrinol       Date:  1985-12       Impact factor: 4.286

View more
  2 in total

1.  Opioid binding in the rostral hypothalamus is reduced following lesion of the ventral noradrenergic tract in female rats.

Authors:  R G Dyer; N Parvizi; S Hollingsworth; S Mansfield; R P Heavens; R J Bicknell; D J Sirinathsinghji
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

2.  Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy.

Authors:  Kazuyoshi Shigehara; Kouji Izumi; Kazufumi Nakashima; Shohei Kawaguchi; Takahiro Nohara; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Transl Androl Urol       Date:  2020-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.